External funding opportunities
Sobi welcomes requests for grants to fund independent medical education and research.
Educational grants
These grants are provided to support bona fide, independent medical educational initiatives. Their primary purpose is to maintain, develop, or increase the knowledge, skills, and/or professional performance of healthcare professionals.
Educational grants can include activities for. but are not limited to disease awareness, patient education and medical writing support.
Educational initiatives may be accredited or non-accredited and must be in the field of Sobi's therapeutic areas of interest. Please see below.
Research Grants
These grants are provided to advance medical or scientific knowledge. Sobi welcomes requests for grants to fund independent research, in the field of Sobi's therapeutic areas of interest. Sobi also welcomes applications for Investigator Sponsor Studies.
Applying for support
Grant support can only be provided to eligible organizations, not to individual healthcare professionals or for the benefit of an individual person or persons. Eligible organizations (legal entities) may include, but are not limited to:
- Academic medical centers and medical universities
- Hospitals
- Professional medical associations/societies
- Accredited continuing medical education providers
Considerations and minimum requirements
Submission of a grant request does not guarantee approval. All decisions regarding funding are made at the discretion of Sobi. The requester must be prepared to provide additional documentation and/or written clarifications upon request to enable a complete assessment. If approved, a contract will be required to document appropriately the funding purpose and other compliance requirements.
To be considered, each request must:
- Be unsolicited
- Be free from Sobi influence
- Be free from promotional biases
- Seek to close an identified educational gap
- Demonstrate value for patients and/or the healthcare sector in terms of advancing research
- Be submitted a minimum of 90 days prior to the start date
- Provide expected tangible outcomes
- Include relevant supporting documents as listed below
Supporting Documentation
- A signed request letter by authorized individual(s) on organizational letterhead and/or from an institutional email account (excluding services like Hotmail and Gmail), which adequately describes how the requested funding will be used, the details of the proposed activity and the anticipated outcomes
- Transparent disclosure of the recipient of the funds, including details of any payments to government officials or healthcare professionals (if applicable) and associated rationale (e.g. service description and number of hours for professional fees)
- A detailed budget breakdown allowing Sobi to assess the amount of funding requested (lump sum budgets will be rejected)
- Whether the activity would be supported by other funding sources or by Sobi only
- For events: as applicable, including but not limited to: agenda, hospitality details, venue, details on use of funding used to cover costs of travel or accommodation for healthcare professionals or government officials, expected number of attendees
What Does Not Fall Under the Grant Definition
- Sponsorships
- Investigator Sponsor Studies
- Corporate memberships
- Fellowships
- Patient Organisation (PO) requests
Areas of interest per Therapeutic Area
Haematology
Haemophilia
- Disease pathophysiology and epidemiology
- Patient care and disease management
- Real-world evidence and health outcomes research, including registry-based studies
- Medical education addressing unmet needs in haemophilia
Aplastic Anaemia
- Preclinical/translational studies exploring avatrombopag's mechanism of action in Aplastic Anaemia
Paroxysmal nocturnal Haemoglobinuria (PNH), complement mediated kidney diseases
- Real-world or health outcomes (e.g. PROs) studies/registries
Diffuse large B-cell lymphoma (DLBCL)
- Real-world or health outcomes (e.g. PROs) studies/registries
- Mechanism of action and antigen expression including preclinical studies
- Treatment sequencing in DLBCL
Myelofibrosis
- Disease management and treatment landscape
- Real-world or health outcomes studies (e.g. patient reporter outcomes) registry research
Immunology
VEXAS Syndrome
- Disease management and treatment landscape
- Real-world or health outcomes studies (e.g. patient reported outcomes) registry research
Autoinflammatory diseases, HLH and other hyperinflammatory conditions that may be driven by excess IFNy
- Real-world or health outcomes (e.g. patient reporter outcomes) registry research
- The role of IFNγ in driving disease pathophysiology
Hyperinflammatory sepsis and dysregulated immune responses associated with IFNγ pathway activation
- Studies investigating the role of IFNγ pathway activation in sepsis pathophysiology, disease progression, and clinical outcomes
- Identification and characterization of sepsis populations with evidence of IFNγ-driven hyperinflammation, including biomarker development and validation, patient stratification approaches, and natural history studies
Gout (inflammatory arthritis caused by uric acid)
- Optimizing gout disease management and characterizing the evolving treatment landscape
- Evaluating the impact of comorbidities on gout burden, disease progression, and clinical outcomes
- Importance of testing and monitoring approaches to inform gout management and patient outcomes
- Addressing unmet needs and care gaps in the management of gout
Nephrology
Complement mediated kidney diseases (C3G/IC-MPGN)
- Real-world or health outcomes (e.g. PROs) studies/registries
- Current treatment controversies (when to start, discontinuation, prophylaxis for transplant, etc)
- MoA of peg and of inhibiting C3 vs. other targets in the complement cascade of C3G/IC-MPGN patients
Specialty Care
Severe hypertriglyceridemia
- Real-world or health outcomes (e.g. patient reported outcomes) registry research
- International registries support
- Research on severe hypertriglyceridemia disease physiopathology and epidemiology
- Improvement of patient care and treatment algorithm for patients with severe hypertriglyceridemia
- Medical education on unmet needs and diagnosis of severe hypertriglyceridemia
Jun, 2026